The effect of an intralesional sustained-release formulation of interferon alfa-2b on basal cell carcinomas.

Abstract	Intralesional interferon alfa-2b has been proven effective in the treatment of basal cell carcinomas. Because nine injections over a 3-week period have been necessary to produce clinically significant cure rates, a sustained-release protamine zinc chelate interferon formulation has been developed. In this study, 65 basal cell carcinomas were treated in one of two dosing schedules with intralesional sustained release interferon alfa-2b (10 million IU per injection). Thirty-three patients received a single injection and 32 patients received one injection per week for 3 weeks. At study week 16, 80% of evaluable tumors treated with three injections and 52% treated with one injection were cured histologically. Two patients discontinued injections because of side effects. A sustained-release protamine zinc preparation of interferon alfa-2b shows promise as a practical, effective, and cosmetically elegant treatment for basal cell carcinoma.
Authors	L Edwards, S B Tucker, D Perednia, K A Smiles, E L Taylor, D J Tanner, E Peets
Journal	Archives of dermatology (Arch Dermatol) Vol. 126 Issue 8 Pg. 1029-32 (Aug 1990) ISSN: 0003-987X [Print] United States
PMID	2383027 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References	Chelating Agents Delayed-Action Preparations Interferon Type I Interferon alpha-2 Interferon-alpha Protamines Recombinant Proteins protamine zinc
Topics	Adult Aged Carcinoma, Basal Cell (pathology, therapy) Chelating Agents (administration & dosage) Delayed-Action Preparations Drug Administration Schedule Esthetics Humans Injections, Intralesional Interferon Type I (therapeutic use) Interferon alpha-2 Interferon-alpha (administration & dosage, adverse effects, therapeutic use) Middle Aged Protamines (administration & dosage) Random Allocation Recombinant Proteins Skin Neoplasms (pathology, therapy) Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!